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Abstract 
H. influenzae is a gram-negative bacterium colonizing the human respiratory tract and is 
responsible for hundreds of thousands of deaths annually.  To aid in persistence and infection in its 
human host H. influenzae produces many secreted virulence factors including an IgA1 protease 
(IgAP).  This enzyme selectively cleaves human and great ape IgA1 in its proline, serine and 
threonine rich flexible hinge region.  This enzyme is a type Va autransporter protein and shares 
significant structural homology to the serine protease autotransporters of the Enterobacteriaciae.   
 
The objective of this thesis is to determine a method for the large scale expression of IgAP to allow 
for biochemical characterization and aid in understanding its role in infection and potential as a 
therapeutic for IgA nephropathy.  This thesis presents three strategies for the attempted production of 
this enzyme in Escherichia coli, which is complicated by the inability of the protein to tolerate a 
methionine residue at the N-terminus.  Native synthesis of the protein results in an alanine at the N-
terminus caused by cleavage of the signal peptide during export to the periplasm.  First the gene was 
cloned into the pBAD vector in frame with a viral signal peptide to target expression to the periplasm 
and produce a native N-terminus.  Expression of IgAP in a simple pET vector was attempted, relying 
on the native methionine amino peptidase activity of E. coli. to cleave the N-terminal methionine.  
Finally, a mutant form of the enzyme lacking any methionine residues was expressed into insoluble 
inclusion bodies, purified and after denaturation with guanidine-HCl, the N-terminal methionine was 
cleaved with CNBr. 
 
Through these studies we present several methods for the production of proteins in E. coli 
particularly applicable to proteins that will not tolerate a methionine at the N-terminus.  The methods 
presented were insufficient to produce an amount of soluble, active IgAP as detectable by SDS-PAGE 
and cleavage of the IgA1 heavy chain.  
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Chapter 1 
Introduction 
1.1 Haemophilus influenzae 
The genus Haemophilus is defined as having seven member species, all residing in humans or apes, 
based on sequence analysis of 16S rRNA using the maximum-likelihood method (Rosa & Labedan, 
1998) ⁠.  One member species, Haemophilus influenzae, a pathogen of the human respiratory tract was 
erroneously identified in the 1890s as the causative agent of influenza after which it's named.  It was 
later found to be responsible for many infections including: meningitis (Jones, 1937) ⁠, bacteremic 
pneumonia, otitis media (Bjuggren & Tunevall, 1952) ⁠ and septicaemia (De Navasquez, 1942) ⁠ among 
others (Turk, 1984) ⁠.  H. influenzea is classified into strains based on the serotype of a capsular 
polysaccharide, with six serologically distinct strains (a-f) (Pittman, 1931) ⁠ identified to date.  
Non-typeable strains, lacking a polysaccharide capsule, are present in the respiratory tract of 40-
80% of the population (Turk, 1984) ⁠⁠ and while these strains do not typically cause disease they act as 
opportunistic pathogens. The genome of the non-capsular strain Rd KW20 was the first bacterial 
genome to be sequenced (Fleischmann et al., 1995) ⁠.  
 
Strains presenting the H. influenzae serotype b (Hib) capsule cause most infections, particularly 
children under the age of 5 of which an estimated 247 000-545 000 a year die annually from Hib 
infections (Watt et al., 2009) ⁠.  During the 1990s Hib conjugate vaccines were introduced and have 
been very effective in reducing infections and carriage of H.influenzae serotype b strains (Morris, 
Moss, & Halsey, 2008) ⁠. Worldwide 26% of children are estimated to be vaccinated, however the rate 
of vaccination is much higher in developed countries as compared to less developed countries (Morris 
et al., 2008) ⁠.  As a result other groups including serotype a (Hia) (Ulanova & Tsang, 2014) ⁠ and non-
typeable (NTHi) (Murphy et al., 2009) ⁠ (Gkentzi, Slack, & Ladhani, 2012) ⁠ strains are responsible for 
a greater proportion of infections.   
 
As mentioned previously H. influenzae colonizes the human respiratory tract and is an obligate 
pathogen, well adapted to its niche.  This can be demonstrated by comparing H. influenzae to 
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Escherichia coli, another human pathogen and γ-proteobacteria, that unlike H. influenzae is able to 
live in a diverse array of environments (Neidhardt & Curtiss, 1996) ⁠.  H. influenzae and E. coli share a 
common ancestor whose genome is believed to be close in size to that of E. coli, at 4.7 Mbp while the 
genome of H. influenzea is significantly smaller at 1.8Mb (Rosa & Labedan, 1998) ⁠.   
 
In order to persist and cause infections H. influenzae has developed several strategies against 
attacks from the human immune system including: capsular polysaccharide, lipoolygosaccharide 
(LOS), fimbriae, pili and many outer membrane and secreted proteins (Hallström & Riesbeck, 2010) ⁠.  
The capsular polysaccharide of serotype b strains, composed primarily of a polymer of 
polyribosylribitilphosphate (PRP) (Crisel, Baker, & Dorman, 1975) ⁠, is a major virulence factor 
(Sukupolvi-Petty, Grass, & St Geme, 2006) ⁠.  The outer membrane of H. influenzae contains 
lipooligosaccharides whose carbohydrate antigens mimic those of human cells in order to avoid an 
immune response (Mandrell et al., 1992) ⁠.    Adherence by H. influenzae to human nasopharyngeal 
epithelial cells is enhanced in strains possessing fimbriae, although adherence does not absolutely 
require fimbriae (Loeb, Connor, & Penney, 1988) ⁠.  Pili assist in biofilm formation and allow H. 
influenzae cells to adhere to each other (Murphy & Kirkham, 2002) ⁠.   
 
1.2 Immunoglobulin A 
In human mucosa, including the respiratory tract, immunoglobulin A (IgA) is the predominant 
immunoglobulin and the second most abundant in the sera after IgG (Chodirker & Tomasi, 1963) ⁠.  
IgA has the same basic structure as other immunoglobulins consisting of the two heavy and two light 
chains (Svehag & Bloth, 1970) ⁠ the variable regions of both the heavy and light chain form the Fab 
region.  The peptide portion of the Fc region is formed solely by two heavy chains.   
 
Serum IgA is produced by the bone marrow and is monomeric while secretory IgA is synthesized 
by specialized cells derived from B-lymphocytes in the mucosa aided by other specialized immune 
cells (Underdown & Schiff, 1986) ⁠.  Compared to serum IgA, secretory IgA has a more variable and 
complex structure, involving two IgA molecules linked by disulphide bonds to the 15 kDa J-chain 
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(Koshland, 1985) ⁠.  The J-chain also allows for the pentamerization of IgM and higher order oligomers 
(tri, tetra and pentamers) of IgA are also produced to a lesser extent.  As the mucosal epithelia form a 
barrier, IgA transport into the lumen is mediated by the polymeric immunoglobulin receptor (pIgR).  
IgA binds the pIgR at the basolateral membrane of the mucosal epithelium and travels to the apical 
membrane by transcytosis (Apodaca et al., 1991) ⁠.  During this process a portion of pIgR is cleaved 
and forms covalent attachments to IgA via disulphide bonds, this cleaved segment of pIgR is termed 
the secretory component (SC) (Woof & Kerr, 2006) ⁠.   
 
There are two subclasses of human IgA: IgA1 and IgA2 differing primarily by a 20 amino acid 
insertion present in the heavy chain of IgA1 (Kerr, 1990) ⁠.  This region comprises a duplicated 
octapeptide rich in proline, serine and threonine and forms a flexible linker between the conserved 
(Fc) and antigen binding (Fab) regions.  The linker region contains twelve serine and threonine 
residues for O-glycosylation in addition to two N-linked glycosylation sites at Asn263 and Asn459 in 
the Fc region (Mattu et al., 1998) ⁠.  Analysis of secretory IgA1 by mass spectrometry has found the O-
glycosylation of the hinge region to be quite variable and present studies, while able to identify the 
glycans present are unable to unambiguously assign the precise site and occupancy of these glycans 
(Deshpande, Jensen, Packer, & Kolarich, 2010) ⁠(Zauner et al., 2013) ⁠. 
 
IgA1 molecules with reduced galactose content in their hinge region have been implicated in IgA 
nephropathy (Novak, Julian, Tomana, & Mestecky, 2008) ⁠. IgA nephropathy is characterized by the 
accumulation of IgA1 and to a lesser extent IgG and IgM in the glomerulus of the kidney, which 
causes an autoimmune response leading to reduced kidney function (Wyatt & Julian, 2013) ⁠.  
 
SIgA is present in human milk and is thought to play a role in the immunity of newborn children 
(Hanson & Korotkova, 2002) ⁠.  IgA is a poor activator of the complement pathway as compared to 
IgG and IgM and is only able to activate the complement via the lectin pathway and not the classical 
or alternative pathways (Roos et al., 2001) ⁠. This is not to say that IgA is an ineffective member of the 
immune system, as the human mucosa contains far fewer complement components than the sera 
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(Kilian, Mestecky, & Russell, 1988) ⁠.  The predominant role of SIgA in mucosal immunity is to 
inhibit adherence of bacterial cells to the epithelia of the mucosa and allow for removal from the host 
(Woof & Kerr, 2006) ⁠. 
 
1.3 Immunoglobulin A1 Proteases 
The importance of these molecules in the virulence and persistence of H. influenzae was discovered 
primarily because of their importance in other pathogens.  Recently a more systematic approach to 
determine genes required for H. influenzae persistence and virulence using a murine model and a 
transposon insertion based screen was undertaken (Gawronski, Wong, Giannoukos, Ward, & Akerley, 
2009) ⁠.  This screen identified genes primarily involved in the acquisition of nutrients from the host 
particularly amino acid and nucleotide precursors, proteins protecting against oxidative stress and 
formation of the LPS as well as outer membrane protein (Wong & Akerley, 2012) ⁠.  Unsurprisingly 
one gene not identified by this screen is the immunoglobulin A protease (IgAP), which cleaves 
human IgA1 in its hinge region, which is not present in murine IgA. 
   
IgA proteases are bacterial enzymes that specifically cleave the hinge region of human and ape 
IgA1 between a proline/serine or proline/threonine peptide bond (Plaut, 1983) ⁠.  The first of these 
enzymes was initially identified as belonging to a bacterium present in human fecal matter (Mehta, 
Plaut, Calvanico, & Tomasi, 1973) ⁠ and eventually found in members of the genus Neisseria (Plaut, 
Gilbert, Artenstein, & Capra, 1975) ⁠.  Both gram-negative and gram-positive pathogens have been 
found to possess these enzymes, although not all enzymes are evolutionary related as some species 
contain serine and metallo IgA1 proteases. Serine IgA1 proteases are found in members of the genera 
Neisseria and Haemophilus (Plaut, Flentke, Lynch, & Kettner, 1990) ⁠, while zinc-bearing 
metalloproteases are found in members of the genus Streptococci (Plaut, Gilbert, & Heller, 1978) ⁠, 
Clostridium and Prevotella (Frandsen, Kjeldsen, & Kilian, 1997) ⁠ although the streptococcal enzymes 
are antigenically distinct form those of the latter two genera.   
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The precise site of cleavage in the hinge region varies depending on the particular enzyme.  For 
example an enzyme from H. influenzae cleaves the peptide bond between proline 231 and serine 232, 
while Streptococcal enzymes generally cleave between proline 227 and serine 228 (Batten, Senior, 
Kilian, & Woof, 2003) ⁠.  Proteases found in strains of S. pneumoniae, Streptococcus oralis, 
Streptococcus mitis and Streptococcus sanguis show varying levels of tolerance for substitution of 
hinge residues.  However, it's the S. pneumoniae enzyme that demonstrates the highest tolerance for 
mutated substrates but it will preferentially cleave proline-threonine peptide bonds (Batten et al., 
2003) ⁠.  Enzymes found in Neisseria and Haemophilus have preferred cleavage sites closer to the Fc 
region than streptococcal enzymes.  There are also two distinct types of cleavage, type 1 in which a 
proline-serine bond is cleaved and type 2 where cleavage occurs at a proline-threonine bond (Batten 
et al., 2003) ⁠.     
 
The role that these extracellular enzymes play in pathogenesis expands beyond the cleavage of 
IgA1, the H. influenzae and N. gonorroheae enzymes can also cleave other substrates.  Lysosomal 
associated membrane protein 1 (LAMP1), as its name suggests is an integral membrane protein of the 
lysosome, is cleaved by the gonoccocal IgAP allowing the pathogens to reproduce intracellularly (Lin 
et al., 1997) ⁠(Hauck & Meyer, 1997) ⁠.  The Neisserial enzymes also elicit the production of pro-
inflammatory cytokines, including tumor necrosis factor-α (TNF-α), in a manner independent of 
serine protease activity (Jose, Wölk, Lorenzen, Wenschuh, & Meyer, 2000) ⁠.  
 
1.4 Type V Secretion System 
H. influenzae IgAP is exported to the extracellular media using the type V secretion or 
autotransporter(AT) pathway, which was first discovered in the IgAP of Neisseria gonorroheae 
(Pohlner, J., Halter, R., Beyreuther, K. & Meyer, 1987) ⁠.  More specifically the IgAPs of N. 
gonorroheae and H. influenzea are type Va ATs as opposed to type Vb or Vc ATs.  Proteins 
belonging to the type Va family share a general structure characterized by three domains: an N-
terminal signal peptide, followed by a passenger and finally the C-terminal β-domain (Dautin & 
Bernstein, 2007) ⁠.  The passenger domain carries out the proteins intended function, while the signal 
peptide and β-domain serve as a means of crossing the inner membrane and outer membrane 
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respectively (Desvaux, Parham, & Henderson, 2004) ⁠.  Type Vb autotransporters consist of two 
seperate peptides, one containing the signal sequence and passenger domain and another containing 
the β-domain (Dautin & Bernstein, 2007) ⁠.  All AT passenger domains for which a crystal structure is 
available contain large β-helices, consisting of 3 parallel sheets occasionally with loops present in 
between the turns (Dautin & Bernstein, 2007) ⁠.   
 
The autotransporter pathway is the simplest known method for export of gram-negative bacterial 
proteins as the proprotein is sufficient for crossing the OM.  In the type V secretion system transport 
across the IM occurs co-translationally via the secretory pathway (Brandon et al., 2003) ⁠.  Transport 
through the IM involves the passage of the peptide through the SecYEG complex or Sec translocon, 
however there are two pathways that bring a peptide to the translocon. One method is the signal 
recognition particle (SRP) pathway, in which the SRP binds the signal peptide and allows for co-
translational transport (Luirink & Sinning, 2004) ⁠, the other is the SecAB pathway in which the 
protein is maintained in an unfolded state and transported post-translationally (Valent et al., 1998) ⁠.   
 
Both methods require the presence of an N-terminal signal sequence with three characteristic 
features: the N-terminal n-region, which is often positively charged followed by the hydrophobic h-
region and finally the C-terminal c-region where cleavage by signal peptidase occurs (Martoglio & 
Dobberstein, 1998) ⁠.  The H. Influenzae IgAP signal peptide 
(MLNKKFKLNFIALTVAYALTPYTEA) follows this general structure.  Many ATs contain 
atypically long signal peptides, which slows their transit through the IM and is believed to reduce the 
incidence of folding and misfolding in the periplasm (Peterson, Szabady, & Bernstein, 2006) ⁠.  In the 
periplasm ATs interact with several chaperones: Skp, DegP and SurA to prevent their aggregation and 
misfolding before export across the OM (Knowles, Scott-Tucker, Overduin, & Henderson, 2009) ⁠. 
 
Once the AT has crossed the IM into the periplasm the β-domain is responsible for translocation 
across the OM demonstrated by the fusion of periplasmic proteins with the N. Gonorroheae IgAP β-
domain, which results in there surface exposure (Klauser, T., Joachim, K., Otzelberger, K., Pohlner 
and Meyer, 1993) ⁠.  β-domains are roughly 30kDa in size and possess a β-barrel structure consisting of 
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12-15 strands (Henderson & Navarro-Garcia, 2004) ⁠.  Insertion of the translocator domain into the 
OM was previously thought to be a spontaneous and thermodynamically favourable, with some 
assistance from chaperones, peptidylproline isomerases and disulphide isomerases (Tamm, Arora, & 
Kleinschmidt, 2001) ⁠.  However more recent evidence shows that β-barrel insertion into the OM 
requires the β-barrel assembly machinery (BAM) (Voulhoux, Bos, Geurtsen, Mols, & Tommassen, 
2003) ⁠ and that AT secretion is also BAM dependent (Jain & Goldberg, 2007) ⁠. 
 
The mechanism by which the passenger domain traverses the OM resulting in either localization to 
the OM or cleavage and release to the extracellular media is the least understood part of AT 
biogenesis.    All crystal structures of AT β-domains contain, in addition to the 12 stranded β-barrel, 
an α-helix present in the cavity of the barrel (van den Berg, 2010) ⁠(Zhai et al., 2011) ⁠ (Barnard, 
Dautin, Lukacik, Bernstein, & Buchanan, 2007) ⁠ (Oomen et al., 2004) ⁠ (Tajima, Kawai, Park, & 
Tame, 2010) ⁠(Barnard et al., 2012) ⁠ (Meng, Surana, St Geme, & Waksman, 2006) ⁠.  A model in 
which, the passenger domain is threaded through the central cavity of the β-domain, was first 
proposed but due to the discovery that disulphide bond containing (Veiga, de Lorenzo, & Fernández, 
1999) ⁠ and protease resistant (Brandon & Goldberg, 2001) ⁠ substrates can be translocated has led to 
other models being proposed. Another model of AT transit through the OM involves passage through 
a large pore formed by an oligomeric ring of β-domains (Veiga, de Lorenzo, & Fernández, 2004) ⁠.   
 
The hairpin mechanism involves hairpin formation by the region N-terminal to the β-barrel being 
inserted into the cavity, followed by the threading of the remainder of the molecule in a C- to N-
terminal direction into the extracellular media (Junker, Besingi, & Clark, 2009) ⁠.  This is supported by 
refolding experiments involving the ATs pertactin and Pet, which are mainly β-helical, although Pet 
contains an N-terminal serine protease domain, that revealed a stable, protease resistant C-terminal 
core and an unusually slow refolding rate with little aggregation in vitro (Junker et al., 2006) ⁠(Renn & 
Clark, 2008) ⁠.  The folding of this stable core is believed to provide the energy for translocation as 
there is little ATP in the periplasm and no proton gradient across the OM to couple to as a source of 
energy (Peterson, Tian, Ieva, Dautin, & Bernstein, 2010) ⁠.  Within this model there is still uncertainty 
as to whether the α-helix found in the pore of β-domain crystal structures is present in the pore during 
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translocation or if it is present in the periplasm.  The final model of OM transport of AT proteins is 
the BamA mechanism in which β-domain is still inserted into the OM but the passenger travels 
through BamA to leave the periplasm (Leyton, Rossiter, & Henderson, 2012) ⁠. 
 
Some ATs are cleaved and released from the cell, such as IgAP, while others remain associated 
with the OM via attachment to their β-domain, however amongst cleaved passenger domains there are 
different methods of cleavage (Henderson & Navarro-Garcia, 2004) ⁠.  An E. coli O157:H7 
autotransporter, extracellular serine protease plasmid encoded (EspP), has its passenger domain 
cleaved inside the β-domain cavity and not its serine protease domain (Barnard et al., 2007) ⁠.  The 
cleavage is mediated by the cyclization of the Asn1023 side chain and carbonyl carbon atom, which is 
facilitated by residues inside the β-barrel and several water molecules (Barnard et al., 2012) ⁠, the 
SPATE protein hemoglobin protease (Hbp) autocatalyitcally cleaves its passenger domain in this 
manner (Tajima et al., 2010) ⁠.  While EspP is cleaved roughly in the middle of the β-barrel, NalP 
another AT, is cleaved at the far extracellular end of the β-barrel (Oomen et al., 2004) ⁠.  After 
cleavage the remainder of the α-helix becomes oriented perpendicular to the membrane and a loop on 
the periplasmic side folds down to cover the channel (Tajima et al., 2010) ⁠.  The release of the IgAP 
passenger domain is catalyzed by its serine protease domain rather than residues in the β-domain, as 
mutants of the active site S288 remain associated with the OM (Qiu et al., 1998) ⁠(Plaut, Qiu, & St 
Geme, 2000) ⁠. 
 
1.5 Serine Protease Autotransporters of the Enterobacteraciae (SPATE) 
The sequence similarity amongst all known passenger domains is low, however for all AT with 
structural data available there is a prominent right-handed β-helix.  One group of AT with more 
significant homology between themselves are the SPATE proteins.  While H. influenzae IgAP is not 
technically a member of this group, as the genus Haemophilus belongs to the order Pasteurellales and 
not Enterobacteriales, its general structure is identical.  To date the structure of three SPATE 
passenger domains: Hbp (Otto et al., 2005) ⁠, EspP (Khan, Mian, Sandercock, Chirgadze, & Pai, 2011) ⁠ 
and Pet (Domingo Meza-Aguilar et al., 2014) ⁠, as well as H. influenzae IgAP (Johnson, Qiu, Plaut, & 
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Holyoak, 2009) ⁠ have been solved.  SPATE proteins share the same general structure as other AT, 
they contain an N-terminal signal peptide for crossing the IM, a C-terminal β-domain and finally a 
passenger domain which in addition to a β-helix possesses an N-terminal chymotrypsin-like serine 
protease domain (Dautin, 2010) ⁠. 
 
Serine proteases cleave peptide substrates using a catalytic triad or charge transfer system 
consisting of an aspartate, histidine and a nucleophilic serine (Blow, Birktoft, & Hartley, 1969) ⁠, this 
motif is believed to have evolved four separate times (Dodson & Wlodawer, 1998) ⁠.  The generally 
accepted mechanism of cleavage by the chymotrypsin family of proteases involves substrate binding 
followed by formation of a tetrahedral intermediate formed by nucleophilic attack on the P1 carbonyl 
carbon, by Oγ of the catalytic serine (Blow, 1997) ⁠.  The formation of the oxyanion is stabilized by the 
positively charged backbone amides, referred to as the oxyanion hole (Henderson, 1970) ⁠, collapse of 
the intermediate results in the release of the leaving group, residues P1'-Pn', and the formation of an 
acyl enzyme intermediate (Dixon, Brennan, & Matthews, 1991) ⁠(Press & Sussman, 1991) ⁠.  The 
histidine of the catalytic triad assists in activating a water molecule to attack the acyl-enzyme 
intermediate resulting another tetrahedral intermediate followed by collapse and release of P1-Pn 
(Blow, 1997) ⁠.  While there is direct evidence for the formation of an acyl-enzyme intermediate the 
evidence for a tetrahedral intermediate consists of inhibitors mimicking the transition state (Radisky, 
Lee, Lu, & Koshland, 2006) ⁠, however non-enzymatic hydrolysis reactions are known to involve a 
tetrahedral intermediate (Bender, 1960) ⁠.   
 
SPATEs are members of the chymotrypsin family of serine proteases, which contains the most 
members and are found in all domains of life as well as viruses (Rawlings, Barrett, & Bateman, 
2000) ⁠.  A nomenclature was developed for the general description of peptide substrates and the 
corresponding binding subsites on the protease, the two residues containing the scissile peptide bond 
are termed P1 and P1' (Schechter & Berger, 1968) ⁠.  Residues on the side of the acyl intermediate are 
labelled NH3-Pn...P1, while residues of the leaving group are referred to as P2'...Pn'-COO-.  A similar 
system is used for naming protease residues responsible for substrate binding, the 
Sn...S2,S1,S1',S2'...Sn' (Schechter & Berger, 1968) ⁠. 
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Some SPATEs possess an extremely limited number of substrates while others can cleave a wider 
array of peptides, the serine IgAPs from Haemophilus and Neisseria, for example, are known to 
cleave only two substrates (Lin et al., 1997) ⁠, while others, such as Pic form Enteroaggregative E. coli 
(EAEC), have as many as eight known substrates (Dautin, 2010) ⁠.  The specificity of chymotrypsin-
like serine proteases is determined by the binding subsites as well as surface loops (Perona & Craik, 
1997) ⁠, for example the S1 subsite of trypsin, which prefers substrates with a lysine or arginine in the 
P1 site, consists of a glycine an aspartate as well other residues.  The glycine allows for acomadation 
of larger side chains while the negatively charged aspartate favours positively charged substrates 
(Graf et al., 1987) ⁠.  There are eight loop regions in the chymotrypsin fold that play an important role 
in substrate specificity, loops A, B, C, D and E, which form the basis for certain subsite specificities 
and loops 1, 2 and 3 generally believed to influence the S1 site (Perona & Craik, 1995) ⁠.  Another 
important determinant of substrate specificity is the identity of residues 216 and 226 (based on the 
chymotrypsin numbering), which further splits the chymotypsin family into four sub-groups: 
chymotrypsin, trypsin, elastase and collagenase (Perona & Craik, 1995) ⁠.   
 
The elastase sub-group has a preference for small non-polar residues, such as proline, at position 
P1 of the substrate due to a valine at residue 216 in place of glycine found chymotrypsin (Bode, 
Meyer, & Powers, 1989) ⁠.  The H. influenzae IgAP serine protease domain shows a substrate 
preference similar to elastase as opposed to chymotrypsin, trypsin or collagenase, however there are 
several differences in the composition and length of the aformentioned loop regions, particularly loop 
D (Johnson et al., 2009) ⁠. 
 
1.6 H. influenzae and the Neisseria IgA Proteases 
In addition to the β-helix and serine protease domain IgAP as well as Hbp contain other globular 
domains inserted in between the turns of the β-helix, referred to as domains 2, 3 and 4, although Hbp 
contains only domain 2.  These globular insertions into the helical scaffold are hypothesized to play a 
role in substrate recognition and may account for the extreme selectivity of these enzymes (Johnson et 
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al., 2009) ⁠.  The only other SPATE passenger domains with known structures, EspP and Pet do not 
contain a domain 2 but contain small globular insertions into the β-helix similar to domain 3 in Pet 
and domains 3 and 4 in EspP (Domingo Meza-Aguilar et al., 2014; Khan et al., 2011).  SPATEs 
lacking domain 2 are classified as class-1 while SPATEs containing a chitinase-b like domain 2 are 
labelled class-2 (Ruiz-Perez & Nataro, 2014) ⁠.  The exact role of domain 2 in Hbp has been examined 
by generating a mutant form of the enzyme lacking domain 2, which revealed that it was not required 
for haem binding or cleavage of certain peptide substrates (Nishimura et al., 2010) ⁠.     
 
The first attempt at producing inhibitors specific for the serine IgAPs were based on the 
octapeptide region of the IgA1 hinge, the most effective inhibitor with an IC50 of 50µM, generated 
from this effort contained a cysteine substituted at the P3' position and an acylated N-terminus 
(Burton, Wood, Lynch, & Plaut, 1988) ⁠.  The next effort towards specific inhibitors were once again 
similar in composition to the IgA1 hinge but contained an α-aminoboronic acid mimic of proline, the 
most effective inhibitor from this study (Ac-Ala-Pro-boroPro-OH) had a Ki of 13nm for the H. 
influenzae enzyme (Plaut et al., 1990) 
  
The H. influenzae and Neisseria IgAPs are able to cleave an altered form of IgA2 which contains a 
7 amino acid insertion of the IgA1 hinge region, which suggests that these enzymes only require a 
portion of the hinge region for cleavage (Senior, Dunlop, Batten, Kilian, & Woof, 2000) ⁠.  More 
recently the H. influenzae, Neisseria and Streptococcus IgAPs are able to cleave fluorogenic 
substrates based on the IgA1 hinge region (Choudary, Qiu, Plaut, & Kritzer, 2013) ⁠⁠.  The smallest 
substrate the H. influenzae enzyme is able to cleave is a hexapeptide (PPAPVY) based on the N. 
gonorrheae autoproteolytic site.  Research into the function of these enzymes in pathogenesis, the 
role of domains 2, 3 and 4 and the design of potent inhibitors are active areas of research. 
 
1.7 Recombinant Protein Expression in E. coli 
Many biochemical and structural biology techniques require large amounts of highly pure protein, 
on the order of milligrams, however obtaining that amount of protein from a natural source can be 
prohibitive because of cost, safety or simply unfeasible due to other factors.  Since the molecular 
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biology revolution recombinant protein expression has become de rigueur for almost every lab and 
can be seen in almost every new publication.  There are wide range of hosts, plasmids, selection 
techniques and strategies used in recombinant protein expression but perhaps the simplest and most 
widely used system is E. coli (Rosano & Ceccarelli, 2014) ⁠.    
 
Lineages derived from strains K-12 and B are non-pathogenic and are routinely used in a 
laboratory setting for protein expression (Daegelen, Studier, Lenski, Cure, & Kim, 2009) ⁠.  E. coli will 
grow relatively quickly in a wide range of media, lysogeny broth (LB) is a complex media composed 
of protease digested casein, yeast extract and NaCl (Bertani, 1951) ⁠ and is the most common growth 
media.  When grown at 37°C, with agitation in LB, E. coli grows with a doubling time of 20 minutes 
during the exponential phase of growth (Sezonov, Joseleau-Petit, & D’Ari, 2007) ⁠.  However cell 
growth can be enhanced and protein expression optimized by the use of media supplemented with any 
number of carbon or nitrogen sources, metals, vitamins, inorganic salts and saccharides (Studier, 
2005) ⁠ 
 
While genes can be introduced directly into the E. coli genome, proteins destined for expression are 
generally transformed into E. coli via a plasmid vector, containing at a minimum: an origin of 
replication, a promoter, an antibiotic resistance gene, a transcription initiation and stop site, a 
ribosome binding site and translation stop sequence (Sørensen & Mortensen, 2005) ⁠.  In addition 
proteins may be expressed with a fusion partner to aid in expression, some commonly used fusion 
partners include: maltose binding protein (MBP) (Kapust & Waugh, 1999) ⁠, SUMO (Butt, Edavettal, 
Hall, & Mattern, 2005) ⁠ and glutathione S-transferase (GST) (Smith, Johnson, 1988) ⁠.  The most 
widely used expression system is the pET system, which makes use of the T7 bacteriophage promoter 
and the lac operon to regulate expression using the inducer iso-propylthiogalactylpyranoside (IPTG) 
(Dubendorff & Studier, 1991) ⁠.  A less common system is the pBAD system which makes use of the 
araBAD promoter and uses the L-arabinose operon to control expression (Guzman et al., 1995) ⁠. 
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While the expression of soluble protein is the objective of most expression strategies the expression 
of certain gene products results in insoluble inclusion bodies (Hartley & Kane, 1986) ⁠, in these cases 
there are strategies for the solubilization and refolding of these proteins.  First the inclusion bodies 
must be purified and isolated from the remainder of the cellular contents, then solubilized with either 
high concentrations of urea, guanidine-HCl or detergents, in the presence of reducing agents to 
prevent intramolecular disulfide formation (Basu, Li, & Leong, 2011) ⁠.  Finally the denaturants and 
reducing agents must be removed to allow for refolding, there are a number of methods that may be 
employed including direct dilution (Leong & Middelberg, 2007) ⁠, dialysis and column refolding 
(Schmoeger, Wellhoefer, Dürauer, Jungbauer, & Hahn, 2010) ⁠. 
 
The challenge in expressing H. influenzae IgAP recombinantly is that the native N-terminus of the 
secreted passenger domain is an alanine residue buried in the hydrophobic core of the chymotrypsin 
like serine protease domain (Johnson et al., 2009) ⁠, the addition of a methionine at N-terminus results 
in expression into inclusion bodies.  I will present three strategies for cleavage of the undesired N-
terminal methionine: cleavage by endogenous E.coli methionine aminopeptidase (MAP), co-
expression of IgAP with MAP and finally expression of IgAP in inclusion bodies, chemical cleavage 
of methionine by CNBr and refolding. 
 
1.8 Objectives 
The objective of the work presented in this thesis is to determine an expression system able to 
generate soluble, active H. influenzae IgAP in E. coli without relying on the enzyme’s own catalytic 
activity in sufficient quantities for biophysical and biochemical characterization.  The protein used to 
determine the structure of the enzyme was obtained from the culture media of H. influenzae (Johnson 
et. al., 2009), however this system is dependent on the enzyme’s ability of the passenger domain to 
cleave itself from the β-domain.  Future studies will require mutants potentially lacking in catalytic 
activity therefore an alternate expression system is required, in addition the H. influenzae culture 
media was provided by a collaborator who is no longer able to do so. 
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Previous attempts by former members of the Holyoak lab to determine a suitable expression system 
involved the use of Bacillus megaterium as an expression host, co-expressing IgAP with MAP and 
treatment of IgAP inclusion bodies with MAP in the presence of denaturant.  These methods were 
unable to generate soluble active IgAP in any meaningful amount. 
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Chapter 2 Materials and Methods 
2.1 pBAD-IgAP Cloning and Expression 
2.1.1 pBAD-IgAP Cloning 
H. influenzae IgA1P was cloned into the pBAD/gIII vector using the 5' NcoI and 3' SalI sites, the 
gene was amplified from the pET2(b)-IgAP construct.  The insert was originally obtained from H. 
influenzae genomic DNA.  Sequencing confirmed that the insert had the correct orientation and that 
no unintended mutations were introduced after cloning.  The first two residues immediately following 
the signal sequence cleavage site were mutated to alanine and leucine respectively, to generate the 
native N-terminus, using the quick change mutagenesis kit (Stratagene) and the following primer 
pairs: 
Hi IgA pBAD1 for 
5' ccgttctatagccatagcgccatggtgagagacgatgtgg 3'          
Hi IgA pBAD1 rev 
5' ccacatcgtctctcaccatggcgctatggctatagaacgg 3' 
Hi IgA pBAD2 for 
5' ccgttctatagccatagcgccttggtgagagacgatgtgg 3' 
Hi IgA pBAD2 rev 
5' ccacatcgtctctcaccaaggcgctatggctatagaacgg 3' 
 
Reaction conditions were determined using the QuickChange Mutagenesis kit (Stratagene). 
Polymerase chain reactions (PCR) were incubated with 1µL of DpnI restriction enzyme (New 
England BioLabs) for one hour at 37oC.  To verify that the PCR reaction was successful 25 µL of the 
digested reaction was mixed with 5 µL loading dye and then run on a 0.8% agarose gel containing 
RedSafe dye (Intron Biotechnology) for visualization under UV light.  1-5 µL of successful reactions 
was used to transform chemically competent cells of XL-1 Blue E. coli., single colonies were used to 
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inoculate 5mL cultures of LB media containing 100 µg/mL of sodium ampicillin and grown overnight 
in shaking incubator at  37oC.  Plasmid DNA was isolated from the overnight cultures using a 
GENEJet Plasmid Miniprep Kit (Thermo Fisher) and eluted in 50 µL of elution buffer, a nanodrop 
spectrophotometer (Thermo Fisher) was used to measure the absorbance of light at 260 nm in order to 
determine the concentration of DNA present in the sample.  To ensure that no unintended mutations 
were introduced, several clones were sent for DNA sequencing of the entire IgAP gene and successful 
clones were used to transform BL-21 (DE3) E. coli cells for expression. 
 
2.1.2 pBAD-IgAP Expression 
100 uL of a 5mL culture of LB media containing 100 µg/mL ampicillin, grown overnight, carrying 
the pBAD/gIII-IgA1P construct, were used to inoculate a 10 mL LB culture containing 100 µg/mL 
ampicillin.  The cultures were grown in a shaking incubator to an OD600 of 1.0 then induced using 100 
µL of 0.002-20% w/v L-(+)-arabinose to give a final concentration of 0.00002-0.2% w/v.  Expression 
was carried out at 37oC for hours with 1mL samples of culture media being collected immediately 
prior to and 4 hours after induction, the OD600 was determined using a UV-Vis spectrophotometer 
(Cary).  Another trial was conducted by inducing the cells at 25oC and collecting samples 0, 24, 48 
and 72 hours after induction. 
 
The cells collected from the expression media were analyzed centrifuge at 14000 rpm for 1 minute 
then resuspended in a lysis buffer containing 10mM Tris-HCl pH 8, 1mM EDTA and 20% sucrose to 
give an OD600 of 5.  To lyse the outer membrane and release the contents of the periplasm through 
osmotic shock the cells were incubated on ice for 10 minutes then pelleted via centrifugation at 14000 
rpm for 1 minute at 4oC.  The supernatant was discarded and the cells were resuspended in a buffer 
containing 10 mM Tris-HCl pH 8.0 and 1 mM EDTA, incubated on ice for 10 minutes then 
centrifuged at 14000 rpm for 10 minutes at 4oC.  The supernatant, corresponding to the periplasmic 
fraction of the cells, was precipitated using trichloroacetic acid (TCA).  1 mL of periplasm was mixed 
with 250 µL of 100% TCA and incubated on ice for 30 minutes then centrifuged for 10 minutes at 
14000 rpm.  The supernatant was removed with care and the pellet washed with 200 uL ice-cold 
acetone followed by centrifugation at 14000 rpm for 10 minutes twice.  The final pellet was 
resuspended in 20 µL SDS-PAGE sample buffer and analyzed on a 12% gel. 
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Expression was also carried out by inducing cells with 20%-0.002% w/v  L-(+)-arabinose at 25oC, 
1 mL samples were taken immediately before, and 24, 48 and 72 hours after induction. 
 
2.2 pET24(b)-IgAP and pDUET-IgAP-MAP Expression 
Expression studies to examine the role of temperature, amount of inducer, E. coli strain and 
expression media were undertaken.  E. coli BL-21(DE3) cells transformed with the pET24(b)-IgAP 
construct were expressed at 37°C, 28°C and 21°C and induced with 0.1 mM, 1 mM and 5 mM IPTG, 
expression was monitored over the course of 4 hours, samples of the cell culture were collected.  To 
analyze the soluble fraction cells were pelleted by centrifugation at 5000 g for 5 minutes and then 
sonicated for a total of 2 minutes using a cycle of 10 seconds on 50 seconds off. 
 
C41 (DE3) cells were transformed with the pET24(b)-IgAP construct were grown in super broth, 
LB and M9 minimal media, cells were induced with 0.4 M IPTG and grown at 20°C after induction.  
To enrich for IgAP samples were incubated with Ni-NTA resin (BioRad) after lysis, the resin was 
boiled in SDS-PAGE sample buffer to elute the protein and analyzed by SDS-PAGE.  
 
2.3 pET24(b)-IgAP Insoluble Expression and Refolding 
2.3.1 Generating a Construct with Fewer Methionine Residues 
IgAP contains 6 methionine residues: M74, M117, M167, M635, M647 and M655, using the existing 
x-ray crystal structure of IgAP it was determined whether the residues were either buried in the 
hydrophobic core or exposed to solvent.  Residues M74, M167, M635, M647 and M655 were found 
buried in a hydrophobic environment and thus mutated to leucine while M117 was found to be 
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exposed to solvent and was converted to arginine.
 
Figure 2-1 Location of the three methioinine residues (M74, M117 and M167) present in the N-
terminal serine protease domain of IgAP.  Loop regions are coloured identically to the figures 
in Johnson, 2009 (Johnson, et. al., 2009).  The side chains of the methionine residues and the 
catalytic triad are depicted as cylinders. (PDB: 3H09). 
 
M74 is located in an N-terminal extension not found in elastase, M117 is located on loop E and M167 
is located on a β-strand adjacent to the aspartate of the catalytic triad.    M635, M647 and M655 are 
located in domain 2 a globular insertion in the β-helical domain. 
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Figure 2-2 Location of methionine residues in Domain 2 of IgAP, loop regions and domains are 
coloured identically to the figures presented in Johnson, 2009 (Johnson, et. al., 2009).  The side 
chains of the methionine residues are depicted as cylinders.  (PDB:3H09). 
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The mutations were generated using the following primer pairs, the mutated codon is bolded and 
underlined for emphasis: 
M74L 
F 5' cctaatggcattccgttgattgattttagtgttgtgg 3' 
R 5' ccacaacactaaaatcaatcaacggaatgccattagg 3' 
M117R 
F 5' gggaacttaaatggcaataggaataatggcaatgc 3' 
R 5' gcattgccattattcctattgccatttaagttccc 3' 
M167L 
F 5' ccgtgaagactactatctgccacgtcttgataaattg 3' 
R 5' caatttatcaagacgtggcagatagtagtcttcacgg 3' 
M635L 
F 5' gaaaattggctatatttgggtaaaacttccgatgaagcc 3' 
R 5' ggcttcatcggaagttttacccaaatatagccaattttc 3' 
M647L 
F 5' gccaaaagaaatgtattgaaccatatcaacaacgtatg 3' 
R 5' catacgttgttgatatggttcaatacatttcttttggc 3' 
M655L 
F 5' ccatatcaacaacgagcgtttgaatggctttaacgg 3' 
R 5' ccgttaaagccattcaaacgctcgttgttgatatgg 3' 
 
PCR reaction conditions were conditions were made following the QuickChange Mutagenesis kit 
(Stratagene). The remainder of the cloning process was carried out identically to that of section 2.1 
except that 50 µg/mL kanamycin was used to select for transformants instead of 100 µg/mL 
ampicillin. 
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2.3.2 pET24(b) Expression of Inclusion Bodies 
To generate inclusion bodies 1.5L of LB media containing 50 µg/mL kanamycin was inoculated 
with a 50 mL culture grown overnight at 37oC.  The cultures were grown to an OD600 of 1.0 then 
induced with IPTG to a final concentration of 1 mM and grown for 4 hours after induction.  Finally 
the cells were harvested from the media by centrifugation at 5000 g for 15 minutes, cell pellets were 
stored at -80oC until needed. 
 
2.3.3 Isolation and Purification of Inclusion Bodies 
The cell pellet was lysed by passage through an emulsifier twice at ~17000 psi, 10% Triton X-100 
detergent was added to the lysate to a final concentration of 1%v/v.  The insoluble fraction was 
obtained by centrifugation at 24000 g for 15 minutes, the resultant pellet was washed twice in a buffer 
containing 0.1% Triton X-100 detergent to remove lipids and lipid soluble proteins.  Resuspension of 
the inclusion bodies was achieved by dissolving the pellet, in a buffer containing 6 M Guanidine-HCl 
and 25 mM HEPES pH 7.5, overnight at 4oC .  The sample was centrifuged at 24000 g for 15 minutes 
once more to remove any material that is still insoluble and then the supernatant is incubated with Ni-
NTA resin for 30 minutes while stirring.   The resin was washed with roughly 300 mL of 6 M 
Guanidine-HCl pH7.5 until the A280 is less than 0.1, to elute the sample the column is washed in 
roughly 50 mL of 6 M Guanidine-HCl pH 0. 
 
2.3.4 Cleavage of N-terminal Methionine using CNBr 
CNBr was added to the sample for a final concentration of 50 mg/mL and left stirring at room 
temperature in a sealed light-proof beaker.  The reaction was neutralized by the addition of 3 M Tris 
until the solution yielded a pH of 7.5 by monitoring the reaction with a pH meter (Fisher).  To 
visualize the samples by SDS-PAGE 50 µL of the cleavage reaction was diluted to a final volume of 
1 mL in 25 mM HEPES pH 7.5, precipitated by the addition of 200 µL TCA, incubated on ice for 30 
minutes, centrifuged at 14000 g and the pellets were dissolved in 20 µL of SDS sample buffer.  A 
construct omitting the M167L mutant was used to monitor the cleavage reaction via SDS-PAGE. 
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2.3.5 Refolding of CNBr Cleaved Protein 
The different methods for refolding of IgAP treated with CNBr are listed in Table 2.1 below with a 
more detailed procedure for each of the methods in the following sub-sections. 
 
Table 2-1 Attempted Refolding Conditions:  All refolding buffers also contained 25 mM 
HEPES, the pH was adjusted to 7.5 using either 6 M HCl or 10 M NaOH. 
Condition Method [Initial]$ [Final]$ GSH* L-Arg# 
A Column 8 M 0.5 M N N 
B Dilution 8 M 0 M N N 
C Dilution 8 M 0.5 M N N 
D Dilution 8 M 0.5 M Y N 
E Dilution 8 M 0.5 M Y Y 
F Dialysis 8 M 0.5 M N N 
G Dialysis 8 M 0.5 M Y N 
H Dialysis 8 M 0.5 M Y Y 
I Dialysis 8 M 0.5 M* Y Y 
*GSH indicates that 5 mM reduced glutathione (GSH) and 0.5 mM oxidized glutathione (GSSG) was 
included during refolding, #L-Arg indicates that 400 mM L-arginine was included in the refolding 
buffer.  $[Initial] and [Final] refer to the initial and final concentration of urea.  In condition I dialysis 
was carried out stepwise with the sample being dialyzed overnight against 4 M, 2 M and finally 0.5 M 
urea containing buffers. 
 
2.3.5.1 On Column Refolding 
After quenching of the CNBr reaction with 3 M Tris the protein was incubated at 4oC with Ni-NTA 
resin equilibrated in 8 M urea, 25 mM HEPES pH 7.5 for 30 minutes while stirring.  The column was 
washed with a linear gradient of urea from 8 M to 0.5 M over 200 mL, the protein was then eluted 
with a buffer containing 300 mM imidazole and 25 mM HEPES pH 7.5.  To monitor the elution of 
protein from the column the absorbance of the solution at 280 nm was measured. 
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2.3.5.2 Refolding by Direct Dilution 
CNBr digested IgAP was added directly to the refolding media over the course of 15 minutes, the 
sample was stirred so that rapid mixing occurred.  Digested protein was diluted in a volume 99 times 
larger than the sample volume equilibrated at 4oC and left overnight to ensure folding was completed.  
Samples were concentrated in an Amicon nitrogen concentrator equipped with a 30 kDa filter until 
the sample reached a volume of 1-5mL.   
 
2.3.5.3 Refolding by Dialysis 
Samples where refolding was attempted by dialysis were placed in 10 kDa molecular weight cut-
off SnakeSkin dialysis tubing (ThermoFisher) overnight.  The volume of the refolding solution was 
always at least 500 times larger than the contents of the dialysis tubing.  To remove precipitate 
formed during dialysis the samples was centrifuged at 5000 g for 15 minutes at 4°C. 
 
2.3.6 Analysis of Refolded Protein 
2.3.6.1 IgA1 Cleavage Assay 
The primary method used to determine whether the sample was refolded was to assess its 
enzymatic activity, this was achieved by incubating potentially refolded protein with human IgA1 
isolated from human sera (provided by Dr. A. G. Plaut, Tufts University Medical Centre).  To 
determine whether the protein was active 5 µL of IgA1 was incubated with 10 µL of IgAP overnight 
at 30oC and room temperature then half of the reaction was analyzed by SDS-PAGE to determine if 
the heavy chain of IgA had been cleaved. 
 
2.3.6.2 Secondary Structure Analysis Using Circular Dichroism Spectrophotometry 
CD spectrophotometry was used to assess the secondary structure of any potentially refolded 
species.  Samples were dialyzed overnight into 10 mM PO4 pH 7.5 and concentrated in a centrifugal 
concentrator, with a 10 kDa size cutoff, to at least 10 µM for analysis and finally degassed before a 
spectra was collected.  The ellipticity was measured using a Jasco J-715 spectrophotometer scanning 
from 260-190 nm in 1 nm steps, with a response time of 0.125 s and a path length of 0.1 cm.  A 
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spectra was collected first on a sample of 10 mM PO4  pH 7.5 in order to generate a blank, each 
spectra was generated by taking the average of 8 scans.   
 
To calculate the amount of basic secondary structural elements present in the folded wild-type 
IgAP the PDB 3H09 was submitted to the 2Struc server (http://2struc.cryst.bbk.ac.uk/twostruc). 
 
CD spectra were analyzed using the DichroWeb server: 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml), which provides a single interface for several 
secondary structure determination programs.  Only programs able to interpret data between 190-260 
nm were used.      
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Chapter 3 Results and Discussion 
Herein I present three strategies for the expression of the H. influenzae IgAP in E. coli, all strategies 
employ different means for cleaving the problematic N-terminal methionine.  The first system makes 
use of the pBAD vector to target IgAP to the periplasm via an N-terminal signal sequence, which 
generates a native N-terminus.  The second strategy makes use of the native methionine 
aminopeptidase activity of E. coli to cleave the protein produced from a pET vector.  The final 
strategy relies upon the ability of CNBr to specifically cleave peptide bonds C-terminal to methionine 
residues.  The construct for this expression strategy required that all methionine residues be mutated 
to other residues so that CNBr didn’t cleave the peptide anywhere other than at the N-terminus.  To 
assess whether the protein was folded and active circular dichroism spectroscopy and a gel based 
cleavage assay of human IgA1 were employed.  Included as a positive control for the IgA1 cleavage 
assay are two lanes of a 12% SDS-PAGE gel.  The first lane contains IgA1 incubated overnight at 
30°C and in the second lane IgA1 incubated overnight at 30°C in the presence of IgAP produced by 
another member of the lab.      
 
3.1 pBAD-IgAP Cloning and Expression 
3.1.1 pBAD-IgAP Cloning 
The H. influenzae IgAP passenger domain (residues 26-989) was successfully ligated into the 
pBAD vector.  Sequencing of the pBAD-IgAP construct revealed that the insert was ligated in the 
correct orientation and that no unintended mutations were introduced. 
 
3.1.2 pBAD-IgAP Expression 
Expression of the pBAD-IgAP construct at 37oC results in a large band, corresponding to the 
expected size of the IgAP passenger domain, the amount of protein produced appears to demonstrate 
a positive correlation with the amount of L-(+)-arabinose used to induce the culture. 
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Figure 3-1 12% SDS-PAGE showing total protein at 0 and 4 hours after induction with 0.002-
20% L-(+)-arabinose. 
 
Analysis of the periplasmic fraction using osmotic shock to lyse the outer membrane followed by 
TCA precipitation to concentrate the samples followed by SDS-PAGE analysis did not yield any 
detectable protein corresponding to the expected size of IgAP.  Incubation of the total and periplasmic 
fractions with IgA did not result in any detectable cleavage of the IgA heavy chain corresponding to 
IgAP activity. 
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Figure 3-2 12% SDS-PAGE containing total and periplasmic protein as well as IgA incubated 
with the periplasmic fractions. 
 
The roughly 100 kDa band slightly visible in the periplasmic fractions is attributed to spillover 
from the lanes containing the total protein fractions and not to any soluble IgA found in the 
periplasm. 
 
The inability to produce any detectable amount of protein by SDS-PAGE or the IgA cleavage assay 
and the presence of large amounts of insoluble protein indicates that the protein is being expressed 
but that misfolding is occurring.  It is likely that cleavage of the signal sequence could be the rate 
limiting factor if the rate of production by the ribosomes overwhelms the machinery of the secretory 
pathway leading to a surplus of IgAP containing a signal sequence in the cytoplasm.  The obvious 
remedy   would be to reduce the rate of protein production by either lowering the temperature of the 
expression or by lowering the amount of L-arabinose or some combination of both.  However as seen 
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in Figure 3-1 this decreases the rate of production to such an extent that no protein can be detected 
soluble or otherwise.  Potentially other signal peptides including the native H. influenzae IgAP in 
addition to other signal peptides could have been incorporated into the construct to increase the 
efficiency of protein over-expression.    
 
3.2 pET24(b)-IgAP and pDUET Soluble Expression 
The SDS-PAGE analysis of the expression conditions performed by Matthew Macleod as part of 
his Biology 499 research project are located in Appendix B, the results of those gels are summarized 
here. 
 
The expression conditions carried out in attempt to generate soluble IgAP using the pET24(b)-
IgAP and pDUET-IgAP-MAP constructs were unable to produce any soluble protein as detectable by 
SDS-PAGE.  Attempts to purify the soluble fraction via Ni2+ chromatography did not result in any 
soluble protein visible by SDS-PAGE, in addition the products of these expressions were unable to 
cleave the heavy chain of IgA1.  Attempts at replicating the optimal expression conditions outlined in 
a previous study, which reported yields of 20-40mg/L, were unsuccessful in generating any soluble 
protein. 
 
3.3 pET24(b)-IgAP Insoluble Expression and Refolding 
3.3.1 Generating a Construct with Fewer Methionine Residues 
DNA sequencing of a construct containing mutations: M74L, M117R, M167L, M635L, M647L 
and M655L and another containing mutations  M74L, M117R, M635L, M647L and M655L revealed 
that all intended mutations were successfully introduced and that no unintended mutations were 
present.  Sequencing data aligned against the IgAP coding sequence is included in Appendix A. 
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3.3.2 pET-24(b)-IgAPΔM 
The pET24(b)-IgAPΔM construct was successfully transformed into BL-21(DE3) E. coli cells, 
SDS-PAGE analysis of a culture induced with 1mM IPTG revealed that 4 hours after induction, a 
large band approximately 100kDa in size appeared. 
 
 
Figure 3-3 Expression of pDUET and pET-24(b) IgA1P constructs induced with 1mM IPTG at 
37oC for 4 hours. 
 
The pDUET construct succeeded in producing a large amount of MAP but no detectable amount of 
IgAP. 
 
3.3.3 Isolation and Purification of Inclusion Bodies 
No soluble IgAP was detected by SDS-PAGE or any activity by incubation with IgA1, however 
there was a large amount of IgAP found in the insoluble fraction likely present as inclusion bodies.   
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Figure 3-4 10% SDS-PAGE illustrating the isolation and purification of inclusion bodies from 
E. coli BL-21(DE3) cells transformed with the pET-24(b)-IgAPΔM construct. 
 
Washing of the insoluble pellet with detergent to remove lipids and lipid soluble proteins resulted 
in inclusion bodies with a high degree of purity, Ni2+ affinity chromatography resulted in further 
enrichment of IgAP.  
 
 
3.3.4 Cleavage of the N-terminal Methionine Using CNBr 
To measure the rate and specificity of CNBr cleavage of IgAP a construct omitting the M167L 
mutation was generated.  Incubation with 50mg/mL of CNBr at room temperature showed that the 
cleavage reaction goes to completion after 4 hours and that no non-specific cleavage occurs after at 
least 24 hours.  This demonstrates that cleavage quickly and with high specificity. 
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Figure 3-5 10% SDS-PAGE showing IgAP solubilized in 6M Gu-HCl, pH0 incubated for 24 
hours with 50mg/mL CNBr to measure the specificity and efficiency of the cleavage reaction. 
 
Incubation of IgAP purified in the same manner, but lacking any methionine other than the N-
terminal methionine, does not result in a decrease in size visible by SDS-PAGE as demonstrated by 
Figure 3-4 in which a construct containing no methionine residues (IgAPΔM) was subjected to the 
same chemical treatment. 
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Figure 3-6 10% SDS-PAGE demonstrating the purification, cleavage and quenching of 
IgAPΔM. 
 
Quenching of the CNBr reaction with 3M TRIS appears to result in a loss of sample but this is 
attributed to the high concentration of salts interfering with the TCA precipitation, the amount of 
protein in the sample does not appear to decrease as monitored by the solution's absorbance at 280nm 
(A280)..   
 
3.3.5 Refolding of CNBr Cleaved Protein and IgA Cleavage Assay 
Condition A was the only on-column refolding condition employed and was the first method 
attempted for refolding as we believed that immobilization of the C-terminus would mimic the natural 
folding mechanism of ATs.  After running a gradient from 8M – 0.5M Urea  and eluting the column 
with 300mM imidazole there was no protein detected by  A280 as well as SDS-PAGE . 
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Figure 3-7 10% SDS-PAGE analysis of refolding conditions A and F and IgA cleavage assay 
 
 Unsurprisingly in the absence of any detectable protein Condition A was unable to cleave the 
heavy chain of IgA1. 
 
Condition F was the simplest dialysis experiment attempted for refolding and contained no redox 
buffer system (GSH-GSSG) or other osmolytes (L-Arg).  While there was some detectable soluble 
protein a large amount of precipitate formed overnight in the dialysis tubing resulting in a decrease of 
the band corresponding to IgAP as measured by SDS-PAGE.  This first attempt at refolding by 
dialysis resulted in a sample which could not cleave the IgA1 heavy chain.  
 
Condition G  was a dialysis method that contained a redox buffer system consisting of GSH and 
GSSG, once again a large amount of precipitate formed in the dialysis tubing the sample resulting 
from the clarification of the dialysis by centrifugation was unable to cleave the IgA1 heavy chain as 
seen in Figure 3-8. 
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Figure 3-8 10% SDS-PAGE containing the IgA cleavage assay results for Condition G and C. 
 
Condition C was a direct dilution method, addition of CNBr cleaved protein to the refolding 
resulted in precipitation, after centrifugation to pellet the insoluble precipitate and concentration no 
protein was detectable and the sample was unable to cleave IgA. 
 
Condition B was another direct dilution method however in this attempt an endpoint of 0M Urea 
was chosen as opposed to 0.5M as in Condition C, precipitate formed once again after addition of the 
CNBr cleaved protein as demonstrated in Figure 3-9 this sample was unable to cleave the IgA1 
heavy chain. 
  35 
 
Figure 3-9 10% SDS-PAGE containing the IgA cleavage assays for Condition G and B. 
 
Refolding Condition G was a dialysis method, which used a GSH-GSSG redox buffering system 
and an endpoint of 0.5M Urea.  This sample produced a significant amount of precipitate after 
incubation overnight and was unable to cleave the IgA1 heavy chain, even after 48 hours of 
incubation. 
 
Conditions D and E were the final direct dilution methods attempted for refolding of CNBr 
cleaved IgAP, both Condition D and E contained a GSH-GSSG redox buffer while Condition E also 
contained 0.4M L-Arg as an osmolyte.  Once again both conditions produced a large amount of 
precipitate, analysis by SDS-PAGE did not indicate any soluble protein present in the sample, 
incubation of both samples with IgA was insufficient to affect cleavage of the heavy chain. 
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Figure 3-10 10% SDS-PAGE analysis of refolding Conditions D and E via the IgA heavy chain 
cleavage assay. 
 
Condition C was a direct dilution method containing GSH-GSSG as a redox buffer, addition of the 
cleaved IgAP solution to the refolding solution resulted in a white precipitate.  As shown in Figure 3-
9 Condition C is unable to cleave the IgA1 heavy chain. 
 
The direct dilution methods (Conditions B, C, D and E) for attempted refolding of IgA protease 
appear to result in  complete loss of the sample due to precipitation caused either by the inadequacy 
of the refolding buffer to promote folding or from the inability of the protein to adopt it's native 
structure due to the six amino substitutions required for CNBr cleavage.  As there are an almost 
limitless number of possible additives and permutations possible for refolding buffers given that the 
conditions attempted covered the general classes of additives (redox buffers and osmolytes) no further 
conditions were attempted.  
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Figure 3-11 10% SDS-PAGE analysis of Condition C and H IgA cleavage assay. 
 
Condition H employed dialysis with an endpoint of 0.5M urea in addition GSH-GSSG was 
included as well as L-Arg.  This condition produced precipitate in the dialysis tubing but there was 
still enough protein to be detected by A280 readings as well as SDS-PAGE as indicated by Figure 3-
11.  Incubation of this sample with IgA was none the less insufficient for cleavage of the IgA1 heavy 
chain. 
 
Condition I was a dialysis method similar to Condition H except that dialysis was carried out in a 
stepwise manner with endpoints at 4M, 2M and finally 0.5M urea.  Again some precipitate formed in 
the dialysis bag after incubation overnight, after pelleting the insoluble fraction there was a significant 
amount of soluble protein visible by SDS-PAGE and A280. 
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Figure 3-12 10% SDS-PAGE of Condition I and IgA cleavage assay. 
 
Condition I produced the least precipitate of all attempted refolding conditions but was still unable 
to cleave the IgA1 heavy chain.  This sample could be concentrated to a concentration of roughly 
1.5mg/mL, higher than the samples produced from any other condition, before precipitate started to 
form on the walls of the centrifugal concentrator.  To determine if the aggregation of this species was 
due to the protein adopting a non-native, but still soluble fold, rather than its native fold or if the six 
mutations introduced for CNBr cleavage had rendered the native fold unstable CD analysis of 
Condition I was undertaken. 
 
3.3.6 Analysis of Refolded Protein by Circular Dichroism Spectrophotometry 
As we're unable to produce significant quantities of the wild-type IgAP to use as a positive control 
a measurement of the relative abundance of secondary structure elements was obtained using the PDB 
of the wild-type enzyme and the 2Struc server (2Struc.cryst.bbk.ac.uk). 
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Table 3-1 Secondary structure analysis of H. influenzae IgAP (PDB: 3H09) analyzed by the 
2Struc server using the DSSP method. 
Structural 
Element 
% 
Helix 8.1 
Sheet 38.1 
Other 52.9 
 
Unsurprisingly there is a larger amount of beta strands and sheets and a smaller amount of α-
helices due to the large β-helical stalk and the relatively smaller serine protease domain. 
 
The protein solution produced from Condition I was successfully dialyzed into 10 mM PO4, the 
blank solution (10 mM PO4, pH 7.5) produced a small but noticeable signal and was used to 
normalize the spectra of Condition I. 
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Figure 3-13 Plot of ellipticity vs. wavelength generated from a sample of IgAP Condition I in 10 
mM phosphate, collected on a Jasco J-715 CD spectrophotometer at room temperature. 
 
The spectra was smoothed using the Jasco spectra analyzer software provided with the instrument 
and this data was used as the input for analysis using the DichroWeb server to generate an estimate of 
secondary structure elements. 
 
The programs, which were used for data analysis were SELCON 3, CONTIN and CDSSTR, 
reference sets 4, 7 and 10 were used for those programs requiring a reference. 
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Table 3-2 Results of DichroWeb analysis of Condition I CD spectra. 
Program Helix 1 Helix 2 Strand 1 Strand 2 Turns Unordered Total Reference 
SELCON3 0.071 0.137 0.181 0.079 0.205 0.383 1.056 4 
CONTIN 0.013 0.074 0.227 0.124 0.231 0.331 1 4 
CONTIN 0.018 0.058 0.201 0.107 0.187 0.428 0.999 7 
CONTIN 0 0.079 0.24 0.136 0.129 0.415 0.999 10 
CDSSTR 0 0.09 0.22 0.13 0.24 0.31 0.99 4 
CDSSTR 0 0.02 0.27 0.12 0.17 0.38 0.96 7 
AVERAGE 0.0107 0.076 0.223 0.116 0.194 0.375 1.001 
STDEV 0.028 0.038 0.031 0.021 0.041 0.046 0.031 
 
The results of all the successful runs were averaged and the results were plotted against the 
calculated values generated from the 2Struc server using PDB 3H09 as input. 
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Figure 3-14 Plot of the relative proportion of secondary structure elements as calculated from 
the PDB:3H09 using the 2Struc server and calculated from the CD spectra of IgAP refolded by 
Condition I using the DichroWeb server. 
 
The results of both methods appear close however the large degree of error present in the 
measurement of β-sheet/turn and unstructured regions by 2Struc analysis makes the interpretation of 
the results somewhat ambiguous.  However based on the similarity of the secondary structure 
elements between the wild-type IgAP and methionine deficient IgAP refolded by Condition I it is 
likely that they adopt a similar structure.  This indicates that the inability of the refolded enzyme to 
cleave the IgA1 hinge region is not due to the misfolding of the enzyme but because the six 
substitutions introduced for CNBr cleavage have abrogated its catalyitc activity.   Also of note is the 
fact that IgAPΔM precipitates in solution above a concentration of 1mg/mL whereas the wild-type 
enzyme was stable in solution up to roughly 10mg/ml. 
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Chapter 4 Conclusions and Future Research 
4.1 Conclusions 
The work presented in this thesis provides several possible methods for expression of proteins in E. 
coli, particularly those that are unable to tolerate an N-terminal methionine residue as well as type V 
autotransporters.  These methods are best suited to bacterial proteins that do not require post-
translational modifications.   
 
The pBAD-IgAP construct, under the conditions tested, was unable to generate soluble protein in 
the periplasm to an extent detectable by SDS-PAGE and the IgA cleavage assay but instead resulted 
in large amounts of insoluble protein in the cytosol.  The pET24(b)-IgAP construct failed to produce 
an amount of soluble protein detectable by SDS-PAGE or the IgA cleavage assay under the 
expression parameters carried out.  The pET24(b)-IgAP construct was able to produce a large amount 
of protein as cytoplasmic inclusion bodies, which can be isolated and purified readily.  Refolding 
Condition H and I were able to produce a somewhat soluble species, stable to a concentration of 
roughly 1mg/mL, but was unable to cleave the IgA1 heavy chain.  In this instance refolding by 
dialysis appears to be more effective than either on-column refolding or direct dilution.  Based on the 
analysis of the CD spectra collected on this potentially refolded species appears to have a similar 
secondary structure composition to the wild-type folded protein.  This indicates that the relative 
instability and catalytic deficiency is caused not by the inability of refolding solution to affect 
refolding but due to the six mutations introduced to allow for CNBr cleavage. 
 
4.2 Future Research 
Determining a method for the expression of H. influenzae IgAP will require further optimization of 
the strategies we have adopted here or completely new strategies.  The pBAD-IgAP expression 
system could be optimized by substituting the present signal sequence with any number of other 
gram-negative signal peptides.  The pET-IgAP expression system could be optimized by the 
supplementing the expression media with any number of additives not limited to cofactors, vitamins, 
metals and carbon or nitrogen sources.  There are also several cell  strains which could be used to 
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potentially generate soluble protein, auto-induction media in which both glucose and lactose is 
present could be used.  This system does not require the addition of an inducer at a specific time, 
rather expression is induced once glucose is depleted as glucose is antagonistic to lactose in its 
induction of the lac operon.  The CNBr cleavage strategy using the pET-IgAP construct is perhaps the 
least versatile of the attempted strategies, the major aspect which could be optimized is the 
composition of refolding buffer.  There a large number of pH buffers, osmolytes and other additives 
which could be employed, the denaturant urea could be replaced by a detergent.  However based on 
the CD analysis refolding may not be possible due to the methioinine substitution mutations. 
 
Once acceptable conditions for expression are determined more work to develop a method for the 
expression of the H. Influenzae IgAP on an industrial scale would enable its use as a treatment for 
IgA nephropathy.  Presently there is work being conducted in the pharmaceutical into large scale 
expression of H. Influenzae IgAP, based on publicly available data there has not been any clinical 
trials studying IgAP as a therapeutic against IgA nephropathy.  However there has certainly been 
interest and IgAP is certainly considered a prospective therapeutic for the treatment of IgA 
accumulation in the kidneys. 
 
The SPATEs and the related IgA proteases of H. Influenzae and Neisseria demonstrate extreme 
substrate selectivity, work is needed to determine which structural elements confer them with this 
high degree of selectivity.  In the case of H. Influenzae IgAP, biochemical studies into the particularly 
role of Loop C and D as well as Domain 2, 3 and 4 are needed to understand their role in determining 
substrate preference.  Deletions of theses loops and globular domains as well as their substitution for 
analogous regions in related enzymes and the generation of selected amino acid substitutions in these 
regions could shed light on their function.  Determining the crystal structure of the IgAP-IgA1 binary 
complex would greatly aid the understanding of substrate binding and the catalytic process of the 
enzyme.  This is not be an easy task given the size of both proteins and the potential homogeneity of 
the IgA1 glycans but would provide a wealth of information about substrate recognition and binding 
as well as the structure of IgA1 itself.  There is presently no crystal structure of the entire protein 
likely due to the flexible hinge regions flexibility preventing crystallization, binding and 
immobilization of the IgA1 hinge by IgAP may aid in crystallization. 
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The role of IgAP in H. influenzae infection is still being actively explored and new substrates such 
as LAMP1 may yet be discovered.  There are no animal models for studying IgAP in infection, owing 
to the fact that only the great apes possess an IgA containing the all important hinge region and 
developing a disease model in apes would face numerous ethical and practical challenges.  There are 
murine models of H. influenzae infection, which are generally useful in studying the process of 
infection, however they are particularly ill-suited to study the role of IgAP.  Presently the most 
advanced model able to study the role of IgAP is based on a human epithelial carcinoma cell-line, the 
development of an infection model use non-immortalized, primary cells from the human respiratory 
tract would present a more relevant model of infection. 
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Appendix A 
DNA Sequencing Data 
pET24(b)-IgAPΔM Sequencing 
 
IgAP        gcgttagtgagagacgatgtggattatcaaatatttcgtgattttgcagaaaataaaggg 
pETiga      gcgttagtgagagacgatgtggattatcaaatatttcgtgattttgcagaaaataaaggg 
            ************************************************************ 
 
IgAP        agattttctgttggtgcaacaaatgtggaagtgagagataaaaataaccactctttaggc 
pETiga      agattttctgttggtgcaacaaatgtggaagtgagagataaaaataaccactctttaggc 
            ************************************************************ 
 
IgAP        aatgttttacctaatggcattccgatgattgattttagtgttgtggatgtagataaacgc 
pETiga      aatgttttacctaatggcattccgttgattgattttagtgttgtggatgtagataaacgc 
            ************************ *********************************** 
 
IgAP        atcgccacattgataaatccacaatatgtagtaggtgtaaaacacgttagtaacggcgtg 
pETiga      atcgccacattgataaatccacaatatgtagtaggtgtaaaacacgttagtaacggcgtg 
            ************************************************************ 
 
IgAP        agtgaactacattttgggaacttaaatggcaatatgaataatggcaatgctaaatcgcac 
pETiga      agtgaactacattttgggaacttaaatggcaataggaataatggcaatgctaaatcgcac 
            ********************************** ************************* 
 
IgAP        cgagatgtatcttcagaagaaaatagatatttttccgttgagaaaaatgagtatccaact 
pETiga      cgagatgtatcttcagaagaaaatagatatttttccgttgagaaaaatgagtatccaact 
            ************************************************************ 
 
IgAP        aaattgaatggaaaagcagtaactactgaagatcaaactcaaaaacgccgtgaagactac 
pETiga      aaattgaatggaaaagcagtaactactgaagatcaaactcaaaaacgccgtgaagactac 
            ************************************************************ 
 
IgAP        tatatgccacgtcttgataaatttgttaccgaagttgcaccaatagaggcttcaactgca 
pETiga      tatctgccacgtcttgataaatttgttaccgaagttgcaccaatagaggcttcaactgca 
            *** ******************************************************** 
 
IgAP        agtagtgatgctggcacatataatgatcagaataaatatcctgcttttgtaagactagga 
pETiga      agtagtgatgctggcacatataatgatcagaataaatatcctgcttttgtaagactagga 
            ************************************************************ 
 
IgAP        agtggtagtcaatttatttataaaaaaggagataattacagcttaattttaaataatcat 
pETiga      agtggtagtcaatttatttataaaaaaggagataattacagcttaattttaaataatcat 
            ************************************************************ 
 
IgAP        gaggttggaggcaataatcttaaattggtgggcgatgcctatacctatggtattgcaggc 
pETiga      gaggttggaggcaataatcttaaattggtgggcgatgcctatacctatggtattgcaggc 
            ************************************************************ 
 
IgAP        acaccttataaagtaaaccacgaaaataatggactaattggttttggcaattcaaaagag 
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pETiga      acaccttataaagtaaaccacgaaaataatggactaattggttttggcaattcaaaagag 
            ************************************************************ 
 
IgAP        gaacacagcgatccaaaaggaatattatctcaagatccgcttaccaattatgctgtttta 
pETiga      gaacacagcgatccaaaaggaatattatctcaagatccgcttaccaattatgctgtttta 
            ************************************************************ 
 
IgAP        ggcgacagtggctccccattatttgtatatgatagagaaaaaggaaaatggctttttctt 
pETiga      ggcgacagtggctccccattatttgtatatgatagagaaaaagg-aaatggctttttctt 
            ******************************************** *************** 
 
IgAP        gggtcttatgatttttgggcaggttataacaaaaaatcttggcaagaatggaatatttat 
pETiga      gggtcttatgatttttgggcaggttataacaaaaaatcttggcaagaatggaatatttat 
            ************************************************************ 
 
IgAP        aaacctgaatttgcaaaaactgttctagataaagatactgcaggttctttaactggttct 
pETiga      aaacctgaatttgcaaaaactgttctagataaagatactgcaggttctttaactggttct 
            ************************************************************ 
 
IgAP        aacacccaatacaattggaatcctactggcaaaacaagcgttatttctaatggttctgaa 
pETiga      aacacccaatacaattggaatcctactggcaaaacaagcgttatttctaatggttctgaa 
            ************************************************************ 
 
IgAP        tctctaaatgttgatttattcgatagtagtcaggatactgactctaagaagaacaatcac 
pETiga      tctctaaatgttgatttattcgatagtagtcaggatactgactctaagaagaacaatcac 
            ************************************************************ 
 
IgAP        ggaaaaagtgtgactcttagaggaagtggaacgcttaccttaaataataatatcgatcaa 
pETiga      ggaaaaagtgtgactcttagaggaagtggaacgcttaccttaaataataatatcgatcaa 
            ************************************************************ 
 
IgAP        ggcgcaggcggcttgttctttgaaggagattatgaagttaaaggcacttctgatagtacc 
pETiga      ggcgcaggcggcttgttctttgaaggagattatgaagttaaaggcacttctgatagtacc 
            ************************************************************ 
 
IgAP        acttggaaaggagctggcgtttctgttgctgatggaaaaacagtaacgtggaaagtacat 
pETiga      acttggaaaggagctggcgtttctgttgctgatggaaaaacagtaacgtggaaagtacat 
            ************************************************************ 
 
IgAP        aacccgaaatctgatcgtttagctaaaatcggcaaaggaacattaattgtagaaggaaag 
pETiga      aacccgaaatctgatcgtttagctaaaatcggcaaaggaacattaattgtagaaggaaag 
            ************************************************************ 
 
IgAP        ggagaaaataaaggttcgctaaaagtgggcgatggtactgttatcttaaaacaacaagct 
pETiga      ggagaaaataaaggttcgctaaaagtgggcgatggtactgttatcttaaaacaacaagct 
            ************************************************************ 
 
IgAP        gatgccaataataaagttaaagccttttcacaagtaggtatagtaagtggtcgctcaact 
pETiga      gatgccaataataaagttaaagccttttcacaagtaggtatagtaagtggtcgctcaact 
            ************************************************************ 
 
IgAP        gttgtacttaatgatgataagcaagtagatccaaattccatttactttggctttagaggt 
pETiga      gttgtacttaatgatgataagcaagtagatccaaattccatttactttggctttagaggt 
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            ************************************************************ 
 
IgAP        ggtcgattagatgccaatggcaataatctcacttttgaacatatccgtaatattgatgat 
pETiga      ggtcgattagatgccaatggcaataatctcacttttgaacatatccgtaatattgatgat 
            ************************************************************ 
 
IgAP        ggcgcaagactagtaaatcacaataccagcaaaacctctactgtaacaattactggggaa 
pETiga      ggcgcaagactagtaaatcacaataccagcaaaacctctactgtaacaattactggggaa 
            ************************************************************ 
 
IgAP        agtctaattacagatccaaatacaattactccatataatatagacgcaccagatgaagat 
pETiga      agtctaattacagatccaaatacaattactccatataatatagacgcaccagatgaagat 
            ************************************************************ 
 
IgAP        aatccttatgcctttcgacggattaaagatggaggacagctctatttaaatttggaaaat 
pETiga      aatccttatgcctttcgacggattaaagatggaggacagctctatttaaatttggaaaat 
            ************************************************************ 
 
IgAP        tacacttattatgcgttaagaaaaggtgcgagcactcgttcagaattacctaaaaatagt 
pETiga      tacacttattatgcgttaagaaaaggtgcgagcactcgttcagaattacctaaaaatagt 
            ************************************************************ 
 
IgAP        ggcgaaagcaatgaaaattggctatatatgggtaaaacttccgatgaagccaaaagaaat 
pETiga      ggcgaaagcaatgaaaattggctatatttgggtaaaacttccgatgaagccaaaagaaat 
            *************************** ******************************** 
 
IgAP        gtaatgaaccatatcaacaacgagcgtatgaatggctttaacggttattttggcgaggaa 
pETiga      gtattgaaccatatcaacaacgagcgtttgaatggctttaacggttattttggcgaggaa 
            *** *********************** ******************************** 
 
IgAP        gagggtaaaaataacggtaatctaaatgtgacttttaaaggcaaaagtgagcaaaatcgc 
pETiga      gagggtaaaaataacggtaatctaaatgtgacttttaaaggcaaaagtgagcaaaatcgc 
            ************************************************************ 
 
IgAP        tttttattaacaggcggaacaaaccttaatggcgatttaaaggttgaaaaaggcacatta 
pETiga      tttttattaacaggcggaacaaaccttaatggcgatttaaaggttgaaaaaggcacatta 
            ************************************************************ 
 
IgAP        ttcctttctggcagaccaacaccgcacgcaagagatattgcaggtatttcttcgacaaaa 
pETiga      ttcctttctggcagaccaacaccgcacgcaagagatattgcaggtatttcttcgacaaaa 
            ************************************************************ 
 
IgAP        aaagatcaacactttgctgaaaataatgaagtggtagtagaagatgactggattaaccgc 
pETiga      aaagatcaacactttgctgaaaataatgaagtggtagtagaagatgactggattaaccgc 
            ************************************************************ 
 
IgAP        aattttaaagcaacaaatattaatgtaaccaataacgcaaccctttattcaggtcgcaat 
pETiga      aattttaaagcaacaaatattaatgtaaccaataacgcaaccctttattcaggtcgcaat 
            ************************************************************ 
 
IgAP        gttgcaaacattacttcaaatatcacagcttctgataatgcaaaagtacatattggctat 
pETiga      gttgcaaacattacttcaaatatcacagcttctgataacgcaaaagtacatattggctat 
            ************************************** ********************* 
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IgAP        aaagcaggcgataccgtttgtgtacgttctgactatacgggctatgtgacttgcactact 
pETiga      aaagcaggcgataccgtttgtgtacgttctgactatacgggctatgtgacttgcactact 
            ************************************************************ 
 
IgAP        gacaagttatccgataaagcccttaatagctttaacgccaccaatgtatctggcaatgta 
pETiga      gacaagttatccgataaagcccttaatagctttaacgccaccaatgtatctggcaatgta 
            ************************************************************ 
 
IgAP        aatttatcaggtaatgcaaactttgtcttaggcaaagctaacttattcggcacaattagc 
pETiga      aatttatcaggtaatgcaaactttgtcttaggcaaagctaacttattcggcacaattagc 
            ************************************************************ 
 
IgAP        ggcacgggaaatagccaagtacgtttaaccgaaaatagccattggcatttaacaggcgat 
pETiga      ggcacgggaaatagccaagtacgtttaaccgaaaatagccattggcatttaacaggcgat 
            ************************************************************ 
 
IgAP        agcaatgttaatcagttaaatttagacaaggggcatattcatttaaatgcacaaaacgat 
pETiga      agcaatgttaatcagttaaatttagacaaggggcatattcatttaaatgcacaaaacgat 
            ************************************************************ 
 
IgAP        gcaaataaagtaactacatataacacgctgactgtgaatagcttatcaggtaacggttct 
pETiga      gcaaataaagtaactacatataacacgctgactgtgaatagcttatcaggtaacggttct 
            ************************************************************ 
 
IgAP        ttctattatttaactgatctttccaataaacaaggcgacaaagttgttgtaactaaatcc 
pETiga      ttctattatttaactgatctttccaataaacaaggcgacaaagttgttgtaactaaatcc 
            ************************************************************ 
 
IgAP        gccacaggtaactttacattacaagtggcagataaaacaggcgagcctacaaaaaatgaa 
pETiga      gccacaggtaactttacattacaagtggcagataaaacaggcgagcctacaaaaaatgaa 
            ************************************************************ 
 
IgAP        ctcacgctttttgatgcgtcaaatgctacaagaaataatttgaatgtgtcattagttggg 
pETiga      ctcacgctttttgatgcgtcaaatgctacaagaaataatttgaatgtgtcattagttggg 
            ************************************************************ 
 
IgAP        aataccgttgatttaggtgcttggaaatataaattacgtaatgttaatggacgttacgat 
pETiga      aataccgttgatttaggtgcttggaaatataaattacgtaatgttaatggacgttacgat 
            ************************************************************ 
 
IgAP        ttgtataaccca 
pETiga      ttgtataaccca 
            ************ 
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Appendix B  
SDS-PAGE Results of pET24(b)-IgAP Expression 
 
Figure B-4-1 12%SDS-PAGE containing the results of pET-24(b)-IgAP expression in BL-
21(DE3) cells conducted at 37°C.  
Lane	   Condition	  
1	   Ladder	  
2	   1.0	  mM	  IPTG	  t=0	  
3	   5.0	  mM	  IPTG	  t=0	  
4	   0.1	  mM	  IPTG	  t=1	  
5	   1.0	  mM	  IPTG	  t=1	  
6	   5.0	  mM	  IPTG	  t=1	  
7	   0.1	  mM	  IPTG	  t=2	  
8	   1.0	  mM	  IPTG	  t=2	  
9	   5.0	  mM	  IPTG	  t=2	  
10	   0.1	  mM	  IPTG	  t=3	  
11	   1.0	  mM	  IPTG	  t=3	  
12	   5.0	  mM	  IPTG	  t=3	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13	   0.1	  mM	  IPTG	  t=4	  
14	   1.0	  mM	  IPTG	  t=4	  
15	   5.0	  mM	  IPTG	  t=4	  
 
 
Figure B-4-2 12% SDS-PAGE analysis of pET2(b)-IgAP expression in BL-21(DE3) cells 
conducted at 28°C 
Lane	   Condition	  
1	   Ladder	  
2	   1.0	  mM	  IPTG	  t=0	  
3	   5.0	  mM	  IPTG	  t=0	  
4	   0.1	  mM	  IPTG	  t=1	  
5	   1.0	  mM	  IPTG	  t=1	  
6	   5.0	  mM	  IPTG	  t=1	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Figure B-4-3 12% SDS-PAGE analysis of pET24(b)-IgAP expression in BL-21(DE3) cells 
conducted at 21°C 
7	   0.1	  mM	  IPTG	  t=2	  
8	   1.0	  mM	  IPTG	  t=2	  
9	   5.0	  mM	  IPTG	  t=2	  
10	   0.1	  mM	  IPTG	  t=3	  
11	   1.0	  mM	  IPTG	  t=3	  
12	   5.0	  mM	  IPTG	  t=3	  
13	   0.1	  mM	  IPTG	  t=4	  
14	   1.0	  mM	  IPTG	  t=4	  
15	   5.0	  mM	  IPTG	  t=4	  
Lane	   Condition	  
1	   Empty	  
2	   Ladder	  
3	   1.0	  mM	  IPTG	  t=0	  
4	   5.1	  mM	  IPTG	  t=0	  
5	   0.1	  mM	  IPTG	  t=1	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6	   1.0	  mM	  IPTG	  t=1	  
7	   5.0	  mM	  IPTG	  t=1	  
8	   0.1	  mM	  IPTG	  t=2	  
9	   1.0	  mM	  IPTG	  t=2	  
10	   5.0	  mM	  IPTG	  t=2	  
11	   0.1	  mM	  IPTG	  t=3	  
12	   1.0	  mM	  IPTG	  t=3	  
13	   5.0	  mM	  IPTG	  t=3	  
14	   0.1	  mM	  IPTG	  t=4	  
15	   1.0	  mM	  IPTG	  t=4	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Figure B-4-4 10% SDS-PAGE analysis of IgA cleavage assay conducted with samples in  
Figure4.2-1. 
Lane	   Condition	  
1	   Ladder	  
2	   Negative	  Control	  t=0	  +	  IgA1	  
3	   Negative	  Control	  t=1	  +	  IgA1	  
4	   Negative	  Control	  t=2	  +	  IgA1	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5	   Negative	  Control	  t=3	  +	  IgA1	  
6	   Negative	  Control	  t=4	  +	  IgA1	  
7	   Dye	  Marker	  
8	   1.0mM	  IPTG	  t=0	  +	  IgA1	  
9	   1.0mM	  IPTG	  t=1	  +	  IgA1	  
10	   1.0mM	  IPTG	  t=2	  +	  IgA1	  
11	   1.0mM	  IPTG	  t=3	  +	  IgA1	  
12	   1.0mM	  IPTG	  t=4	  +	  IgA1	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Figure B-4-5 12% SDS-PAGE analysis of pET-24(b)-IgAP expression in C41(DE3) cells carried 
out at 21°C in superbroth. 
 
 
 
 
 
 
 
 
 
 
 
Lane	   Condition	  
1	   Ladder	  
2	   LB	  Negative	  Control	  t=24	  
3	   LB	  trial	  1	  t=24	  
4	   LB	  trial	  2	  t=24	  
5	   SuperBroth	  trial	  1	  t=0	  
6	   SuperBroth	  trial	  1	  t=24	  
7	   SuperBroth	  trial	  2	  t=0	  
8	   SuperBroth	  2	  t=24	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Figure B-4-6 10% SDS-PAGE analysis of the results of Ni2+ affinity chromatography of the 
cultures shown in Figure 4.2-5.  
 
 
 
Lane	   Condition	  
1	   Ladder	  
2	   	  Soluble	  Fraction	  +	  Nickel	  Wash	  
3	   Insoluble	  Lysate	  +	  Nickel	  Wash	  
4	   	  Soluble	  Fraction	  +	  Nickel	  Wash	  +	  Imidazole	  
5	   Insoluble	  Lysate	  +	  Nickel	  Wash	  +	  Imidazole	  
6	   Soluble	  Fraction	  Nickel	  Resin	  
7	   Insoluble	  Fraction	  Nickel	  Resin	  
8	   Soluble	  Fraction	  Nickel	  Resin	  post	  Imidazole	  
9	   Insoluble	  Fraction	  Nickel	  Resin	  post	  Imidazole	  
10	   Empty	  
  58 
 
Figure B-4-7 10% SDS-PAGE analysis of the pET24(b)-IgAP construct expressed in C41(DE3) 
cells carried out at 21°C in LB. 
 Lane	   Condition	  
1	   Ladder	  
2	   Trial	  1	  -­‐	  Soluble	  Fraction	  
3	   Trial	  2	  -­‐	  Soluble	  Fraction	  
4	   Trial	  1	  -­‐	  Insoluble	  Lysate	  +	  1mL	  25mM	  Hepes	  
5	   Trial	  2	  -­‐	  Insoluble	  Lysate	  +	  1mL	  25mM	  Hepes	  
6	   Trial	  1	  -­‐	  Soluble	  Fraction	  +	  Nickel	  Wash	  
7	   Trial	  2	  -­‐	  Soluble	  Fraction	  +	  Nickel	  Wash	  
8	   Trial	  1	  -­‐	  Insoluble	  Lysate	  +	  Nickel	  Wash	  
9	   Trial	  2	  -­‐	  Insoluble	  Lysate	  +	  Nickel	  Wash	  
10	   Empty	  
11	   Empty	  
12	   Trial	  1	  -­‐	  Soluble	  Fraction	  Nickel	  Resin	  
13	   Trial	  2	  -­‐	  Soluble	  Fraction	  Nickel	  Resin	  
14	   Trial	  1	  -­‐	  Insoluble	  Lysate	  Nickel	  Resin	  
15	   Trial	  2	  -­‐	  Insoluble	  Lysate	  Nickel	  Resin	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Figure B-4-8 10% SDS-PAGE analysis of the IgA cleavage assay using samples from Figure 4.2-
6 and Figure 4.2-7.  
Lane	   Condition	  
1	   Ladder	  
2	   Soluble	  Fraction	  +	  Nickel	  Wash	  
3	   Insoluble	  lysate	  	  +	  Nickel	  Wash	  
4	   Soluble	  Fraction	  +	  Nickel	  Wash	  +	  Imidazole	  
5	   Insoluble	  lysate	  	  +	  Nickel	  Wash	  +	  Imidazole	  
6	   Soluble	  Fraction	  Nickel	  Resin	  	  
7	   Insoluble	  lysate	  	  Nickel	  Resin	  	  
8	   Soluble	  Fraction	  +	  Nickel	  Resin	  post	  Imidazole	  
9	   Insoluble	  lysate	  +	  	  Nickel	  Resin	  post	  Imidazole	  
10	   IgA1	  Control	  
11	   Insoluble	  Fraction	  +	  Nickel	  Wash	  
12	   Insoluble	  lysate	  	  +	  Nickel	  Wash	  +	  IgA1	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Figure B-4-9 10% SDS-PAGE analysis of pET24(b)-IgAP expression in BL-21(DE3) cells in M9 
minimal media carried out at 20°C followed by Ni2= affinity chromatography. 
Lane	   Condition	  
1	   Ladder	  
2	   Insoluble	  Lysate	  +	  1mL	  25mM	  Hepes	  
3	   Soluble	  Fraction	  
4	   Insoluble	  Lysate	  +	  Nickel	  Wash	  
5	   Soluble	  Fraction	  +	  Nickel	  Wash	  
6	   Insoluble	  Lysate	  +	  Nickel	  Wash	  +	  Imizadole	  
7	   Soluble	  Fraction	  +	  Nickel	  Wash	  +	  Imizadole	  
8	   Insoluble	  Lysate	  Resin	  
9	   Soluble	  Fraction	  Resin	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Figure B-4-10 10% SDS-PAGE analysis of pET24(b)-IgAP expression in Bl-21(DE3)pLysS cells 
carried out in superbroth at 20°C followed by Ni2= affinity chromatography. 
Lane	   Condition	  
1	   Ladder	  
2	   Insoluble	  Lysate	  +	  1mL	  25mM	  Hepes	  
3	   Soluble	  Fraction	  
4	   Insoluble	  Lysate	  +	  Nickel	  Wash	  
5	   Soluble	  Fraction	  +	  Nickel	  Wash	  
6	   Insoluble	  Lysate	  +	  Nickel	  Wash	  +	  Imizadole	  
7	   Soluble	  Fraction	  +	  Nickel	  Wash	  +	  Imizadole	  
8	   Insoluble	  Lysate	  Resin	  
9	   Soluble	  Fraction	  Resin	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